title: Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.
abstract: BACKGROUND
  Qualitative and quantitative changes in IGRA response offer promise as biomarkers to monitor Tuberculosis (TB) drug therapy, and for the comparison of new interventions. We studied the decay kinetics of TB-specific antigen T-cell responses measured with an in-house ELISPOT assay during the course of therapy.
  
  
  METHODS
  Newly diagnosed sputum smear positive TB cases with typical TB chest radiographs were recruited. All patients were given standard anti-TB treatment. Each subject was followed up for 6 months and treatment outcomes were documented. Blood samples were obtained for the ESAT-6 and CFP-10 (EC) ELISPOT at diagnosis, 1-, 2-, 4- and 6-months. Qualitative and quantitative reversion of the ELISPOT results were assessed with McNemar test, conditional logistic regression and mixed-effects hierarchical Poisson models.
  
  
  RESULTS
  A total of 116 cases were recruited and EC ELISPOT was positive for 87% (95 of 109) at recruitment. There was a significant decrease in the proportion of EC ELISPOT positive cases over the treatment period (p<0.001). Most of the reversion occurred between the start and first month of treatment and at completion at 6 months. ESAT-6 had higher median counts compared to CFP-10 at all time points. Counts for each antigen declined significantly with therapy (p<0.001). Reverters had lower median SFUs at the start of treatment compared to non-Reverters for both antigens. Apart from the higher median counts for non-Reverters, no other risk factors for non-reversion were found.
  
  
  CONCLUSIONS
  TB treatment induces qualitative and quantitative reversion of a positive in-house IGRA in newly diagnosed cases of active TB disease. As this does not occur reliably in the majority of cured individuals, qualitative and quantitative reversion of an IGRA ELISPOT has limited clinical utility as a surrogate marker of treatment efficacy.
authors.affiliation: Bacterial Diseases Programme, Medical Research Council (United Kingdom) Laboratories, Fajara, The Gambia. iadetifa@mrc.gm
authors.forename: Ifedayo M O
authors.initials: IM
authors.lastname: Adetifa
authors.forename: Martin O C
authors.initials: MO
authors.lastname: Ota
authors.forename: Brigitte
authors.initials: B
authors.lastname: Walther
authors.forename: Abdulrahman S
authors.initials: AS
authors.lastname: Hammond
authors.forename: Moses D
authors.initials: MD
authors.lastname: Lugos
authors.forename: David J
authors.initials: DJ
authors.lastname: Jeffries
authors.forename: Simon A
authors.initials: SA
authors.lastname: Donkor
authors.forename: Richard A
authors.initials: RA
authors.lastname: Adegbola
authors.forename: Philip C
authors.initials: PC
authors.lastname: Hill
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014376:Tuberculosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D007371:Interferon-gamma
references.citation: BMC Infect Dis. 2010 May 27;10:138
references.pmid: 20507549
references.citation: AIDS. 2010 Jan 28;24(3):417-26
references.pmid: 20042847
references.citation: Immunol Invest. 2009;38(5):341-9
references.pmid: 19811412
references.citation: Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51
references.pmid: 19026511
references.citation: Pediatr Infect Dis J. 2010 May;29(5):439-43
references.pmid: 20068506
references.citation: J Infect. 2007 Aug;55(2):169-73
references.pmid: 17448540
references.citation: J Exp Med. 1997 Sep 15;186(6):859-65
references.pmid: 9294140
references.citation: Clin Infect Dis. 2005 Jan 15;40(2):273-8
references.pmid: 15655747
references.citation: Respir Med. 2009 Jan;103(1):30-4
references.pmid: 18977647
references.citation: Am J Respir Crit Care Med. 2007 Feb 1;175(3):282-7
references.pmid: 17082492
references.citation: BMC Infect Dis. 2009 Feb 28;9:23
references.pmid: 19250549
references.citation: PLoS One. 2009;4(4):e5187
references.pmid: 19365543
references.citation: PLoS One. 2009;4(1):e4130
references.pmid: 19125189
references.citation: Pediatr Infect Dis J. 2010 Mar;29(3):285-6
references.pmid: 20190616
references.citation: Nat Rev Immunol. 2002 Apr;2(4):251-62
references.pmid: 12001996
references.citation: J Clin Microbiol. 2002 Feb;40(2):704-6
references.pmid: 11826002
references.citation: J Infect. 2009 Mar;58(3):197-204
references.pmid: 18848730
references.citation: Curr Opin Pulm Med. 2009 May;15(3):188-200
references.pmid: 19387262
references.citation: Int J Tuberc Lung Dis. 2006 Feb;10(2):192-8
references.pmid: 16499260
references.citation: Pediatrics. 2006 May;117(5):1542-8
references.pmid: 16651307
references.citation: Eur Respir J. 2010 Aug;36(2):355-61
references.pmid: 19926734
references.citation: J Infect Dis. 2006 Feb 1;193(3):354-9
references.pmid: 16388482
references.citation: BMC Infect Dis. 2006 Mar 30;6:66
references.pmid: 16573826
references.citation: Infect Immun. 2002 Jun;70(6):3026-32
references.pmid: 12010994
references.citation: BMC Infect Dis. 2008 Jan 28;8:11
references.pmid: 18226199
references.citation: Respir Res. 2007 Jan 27;8:5
references.pmid: 17257436
references.citation: PLoS One. 2008 Jan 02;3(1):e1379
references.pmid: 18167540
references.citation: Int J Tuberc Lung Dis. 2010 Jul;14(7):909-15
references.pmid: 20550777
references.citation: Nat Rev Immunol. 2002 Apr;2(4):263-72
references.pmid: 12001997
references.citation: Ann Intern Med. 2007 Mar 6;146(5):340-54
references.pmid: 17339619
references.citation: Int J Tuberc Lung Dis. 2003 Apr;7(4):390-3
references.pmid: 12729346
references.citation: Clin Infect Dis. 2004 Apr 1;38(7):966-73
references.pmid: 15034828
references.citation: Clin Infect Dis. 2005 May 1;40(9):1301-8
references.pmid: 15825033
references.citation: Clin Infect Dis. 2004 Mar 1;38(5):754-6
references.pmid: 14986262
references.citation: J Occup Med Toxicol. 2006 May 23;1:7
references.pmid: 16722616
references.citation: Int J Tuberc Lung Dis. 2007 Mar;11(3):350-2
references.pmid: 17352104
references.citation: BMC Infect Dis. 2007 Oct 25;7:122
references.pmid: 17961228
references.citation: Nat Immunol. 2001 May;2(5):415-22
references.pmid: 11323695